title: Comparative studies on the polyamine metabolism and DFMO treatment of MCF-7 and MDA-MB-231 breast cancer cell lines and xenografts.
abstract: In order to characterize the estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 human breast cancer cells and xenografts, their growth kinetic parameters and some biochemical characteristics concerning the receptor status and polyamine metabolism were determined and compared. The doubling times calculated from the growth curves showed higher proliferation rate of MDA-MB-231 cells, both in culture (21 hours) and in xenograft (9.7 days), in comparison to the MCF-7 cells which had values of 32 hours and 11.6 days, respectively. Growth-dependent changes observed in the intracellular putrescine, spermidine and spermine concentrations indicated a higher activity of polyamine metabolism in the MDA-MB-231 cells and xenograft as well. However, biosynthetic key-enzyme ornithine decarboxylase activity (ODC, EC 4.1.1.17) showed neither characteristic differences between the two types of breast cancer, nor consistent relationship with their proliferation rate. Metabolic alterations of the MCF-7 and MDA-MB-231 cell lines grown in vitro were also reflected in the polyamine composition of their culture medium. Independently of their receptor status, both types of breast cancer were responsive to difluoromethylornithine (DFMO) treatment. DFMO inhibited the ODC activity totally and depleted the cellular polyamine levels. MCF-7 cells in culture were more sensitive to the antitumoral effect of DFMO than the MDA-MB-231 line, while the rate of growth inhibition did not differ significantly in the xenografts. The present results provided further evidence on the different polyamine metabolism of ER-positive MCF-7 and ER-negative MDA-MB-231 human breast cancer cells in vitro and in vivo, suggesting a correlation of hormonal modulation with polyamines as a determinant group of biological response modifiers.
authors.affiliation: National Institute of Oncology, Budapest, Hungary.
authors.forename: T
authors.initials: T
authors.lastname: Kremmer
authors.forename: I
authors.initials: I
authors.lastname: Pälyi
authors.forename: D
authors.initials: D
authors.lastname: Daubner
authors.forename: M
authors.initials: M
authors.lastname: Boldizsár
authors.forename: B
authors.initials: B
authors.lastname: Vincze
authors.forename: E
authors.initials: E
authors.lastname: Paulik
authors.forename: J
authors.initials: J
authors.lastname: Sugár
authors.forename: E
authors.initials: E
authors.lastname: Pokorny
authors.forename: E
authors.initials: E
authors.lastname: Túry
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D000518:Eflornithine / Q000494:pharmacology*; D005260:Female; D006801:Humans; D051379:Mice; D008808:Mice, Inbred CBA; D009368:Neoplasm Transplantation; D011700:Putrescine / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000032:analysis; D013095:Spermidine / Q000378:metabolism*; D013096:Spermine / Q000378:metabolism*; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism / Q000473:pathology
chemical_list: D011960:Receptors, Estrogen; D013096:Spermine; D013095:Spermidine; D011700:Putrescine; D000518:Eflornithine